Drug intelligence / Profile preview

AlgiaPak

Development stage: Preclinical
Lead developer: Algia Pharma
Modality: Small Molecules

Overview

AlgiaPak is a multimodal, non-opioid pain management formulation being developed by Algia Pharma for the treatment of mild-to-moderate acute pain, including perioperative pain. The product combines multiple well-established non-opioid medicines into a single prescribing and dosing format, designed to block pain transmission along various pathways by acting on non-opioid receptors. By providing a standardized approach to hospital-grade multimodal pain control adapted for outpatient use, AlgiaPak aims to offer opioid-level efficacy without the risks of addiction or respiratory depression. The FDA has recommended the 505(b)(2) regulatory pathway for its development, and the company is currently progressing through IND-enabling studies with plans to advance toward Phase 2 clinical trials.

Brand names: AlgiaPak

Beyond the preview

Go deeper on AlgiaPak.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlgiaPak.

Explore the full profile